BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received approval from China’s National Medical...
Drug
Roche’s Ocrevus Approved by China’s NMPA for Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that it has received marketing approval...
AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi...
Sanofi’s Qfitlia Approved by FDA for Hemophilia A and B Prophylaxis
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval from the US Food...
Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
IASO Biotherapeutics’ Fucaso Approved in Macao for Relapsed Multiple Myeloma
China-based IASO Biotherapeutics announced that the New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...
Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention
Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...
Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...
TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies
Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...
NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment
China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed...
Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products...
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the...
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products...
Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...
Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...